Yusuf Erkul

Company: Kernal Biologics

Job title: CEO

Bio:

Seminar: Onco-Selective mRNA Therapeutics for Cancer Immunotherapy

• Cancer ribosomes present unique opportunity for novel, onco-selective mRNA designs
• Onco-selective mRNAs encoding immunogenic cell death proteins results in highly effective oncolytic activity in vitro
• Onco-selective KR-333 mRNA LNPs enable robust antiactivity in syngeneic tumor models

Day: Day One